ENOV Enovis Corp

The average of price targets set by Wall Street analysts indicates a potential upside of 77.3% in Enovis (ENOV). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wilmington, DE, Aug. 08, 2025 ( GLOBE NEWSWIRE ) -- Enovis™ Corporation ( NYSE: ENOV ) , an innovation-driven, medical technology growth company, today announced that its management team will participate in the following investor conferences: ...

Wilmington, DE, Aug. 08, 2025 ( GLOBE NEWSWIRE ) -- Enovis™ Corporation ENOV, an innovation-driven, medical technology growth company, today announced that its management team will participate in the following investor conferences: Canaccord Genuity 45th Annual Growth Conference on Wednesday, ...

Enovis ( NYSE:ENOV ) , a medical technology company focused on orthopedics and recovery products, announced results for Q2 2025 on August 7, 2025. The headline news was a clear beat on both GAAP revenue and non-GAAP adjusted earnings per share.

Enovis (ENOV) delivered earnings and revenue surprises of +6.76% and +1.83%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Wilmington, DE, Aug. 07, 2025 ( GLOBE NEWSWIRE ) -- Enovis™ Corporation ( "Enovis" or "the Company" ) ( NYSE: ENOV ) , an innovation-driven medical technology growth company, today announced its financial results for the second quarter ended July 4, 2025.